JP2009102327A - パピローマウイルス様粒子、融合タンパク質並びにそれらの製造方法 - Google Patents

パピローマウイルス様粒子、融合タンパク質並びにそれらの製造方法 Download PDF

Info

Publication number
JP2009102327A
JP2009102327A JP2008303257A JP2008303257A JP2009102327A JP 2009102327 A JP2009102327 A JP 2009102327A JP 2008303257 A JP2008303257 A JP 2008303257A JP 2008303257 A JP2008303257 A JP 2008303257A JP 2009102327 A JP2009102327 A JP 2009102327A
Authority
JP
Japan
Prior art keywords
papilloma virus
producing
particle
same
fusion protein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2008303257A
Other languages
English (en)
Inventor
Lutz Gissmann
ギッスマン ラッツ
Jian Zhou
ゾウ ジアン
Martin Mueller
ミュラー マーティン
Jeanette Painstil
ペインスティル ジャネット
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Loyola University Chicago
Original Assignee
Loyola University Chicago
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=25940851&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JP2009102327(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from DE19944435907 external-priority patent/DE4435907C2/de
Priority claimed from DE1995126752 external-priority patent/DE19526752C2/de
Application filed by Loyola University Chicago filed Critical Loyola University Chicago
Publication of JP2009102327A publication Critical patent/JP2009102327A/ja
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5258—Virus-like particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20023—Virus like particles [VLP]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Virology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Endocrinology (AREA)
  • Biophysics (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Reproductive Health (AREA)
  • Mycology (AREA)
  • Urology & Nephrology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

【課題】予防的および治療的ワクチン接種のためのワクチンとして好適な組み換え的に製造されたタンパク質並びにＶＬＰｓ、並びにこれらのタンパク質およびＶＬＰｓの製造方法を利用可能にすること。
【解決手段】ウイルス構造タンパク質Ｌ１および／またはＬ２の発現後に形成される組み換え的に製造されたパピローマウイルス様粒子であって、Ｌ１および／またはＬ２タンパク質の１個または複数個の部分が欠失しており、それによりウイルス様粒子を形成する能力が残存していることを特徴とする、上記のパピローマウイルス様粒子。
【選択図】なし

Description

Claims (1)

  1. 明細書に記載の発明。
JP2008303257A 1994-10-07 2008-11-27 パピローマウイルス様粒子、融合タンパク質並びにそれらの製造方法 Withdrawn JP2009102327A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE19944435907 DE4435907C2 (de) 1994-10-07 1994-10-07 Papillomavirusähnliche Partikel und deren Anwendung
DE1995126752 DE19526752C2 (de) 1995-07-21 1995-07-21 Hocheffiziente Bildung von Papillomavirusähnlichen Partikeln

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2005130613A Division JP2005270111A (ja) 1994-10-07 2005-04-27 パピローマウイルス様粒子、融合タンパク質並びにそれらの製造方法

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2011220539A Division JP2012010713A (ja) 1994-10-07 2011-10-04 パピローマウイルス様粒子、融合タンパク質並びにそれらの製造方法

Publications (1)

Publication Number Publication Date
JP2009102327A true JP2009102327A (ja) 2009-05-14

Family

ID=25940851

Family Applications (6)

Application Number Title Priority Date Filing Date
JP8512335A Withdrawn JPH11504801A (ja) 1994-10-07 1995-10-09 パピローマウイルス様粒子、融合タンパク質並びにそれらの製造方法
JP2005130613A Withdrawn JP2005270111A (ja) 1994-10-07 2005-04-27 パピローマウイルス様粒子、融合タンパク質並びにそれらの製造方法
JP2008303257A Withdrawn JP2009102327A (ja) 1994-10-07 2008-11-27 パピローマウイルス様粒子、融合タンパク質並びにそれらの製造方法
JP2011220539A Withdrawn JP2012010713A (ja) 1994-10-07 2011-10-04 パピローマウイルス様粒子、融合タンパク質並びにそれらの製造方法
JP2013112548A Withdrawn JP2013213034A (ja) 1994-10-07 2013-05-29 パピローマウイルス様粒子、融合タンパク質並びにそれらの製造方法
JP2014236222A Expired - Lifetime JP5794747B2 (ja) 1994-10-07 2014-11-21 パピローマウイルス様粒子、融合タンパク質並びにそれらの製造方法

Family Applications Before (2)

Application Number Title Priority Date Filing Date
JP8512335A Withdrawn JPH11504801A (ja) 1994-10-07 1995-10-09 パピローマウイルス様粒子、融合タンパク質並びにそれらの製造方法
JP2005130613A Withdrawn JP2005270111A (ja) 1994-10-07 2005-04-27 パピローマウイルス様粒子、融合タンパク質並びにそれらの製造方法

Family Applications After (3)

Application Number Title Priority Date Filing Date
JP2011220539A Withdrawn JP2012010713A (ja) 1994-10-07 2011-10-04 パピローマウイルス様粒子、融合タンパク質並びにそれらの製造方法
JP2013112548A Withdrawn JP2013213034A (ja) 1994-10-07 2013-05-29 パピローマウイルス様粒子、融合タンパク質並びにそれらの製造方法
JP2014236222A Expired - Lifetime JP5794747B2 (ja) 1994-10-07 2014-11-21 パピローマウイルス様粒子、融合タンパク質並びにそれらの製造方法

Country Status (13)

Country Link
US (6) US6066324A (ja)
EP (2) EP0809700B1 (ja)
JP (6) JPH11504801A (ja)
AT (1) ATE325875T1 (ja)
AU (2) AU4270196A (ja)
CA (1) CA2202090C (ja)
DE (3) DE59511047D1 (ja)
DK (1) DK0809700T3 (ja)
ES (1) ES2264563T3 (ja)
LU (2) LU91401I2 (ja)
NL (2) NL300324I1 (ja)
PT (1) PT809700E (ja)
WO (1) WO1996011272A2 (ja)

Families Citing this family (88)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020164350A1 (en) 1992-09-03 2002-11-07 Lowy Douglas R. Chimeric papillomavirus-like particles
US8062642B1 (en) 1993-03-09 2011-11-22 University Of Rochester Production of papillomavirus capsid protein and virus-like particles
WO1996011272A2 (de) * 1994-10-07 1996-04-18 Medigene Gesellschaft Für Molekularbiologische Diagnostik, Theraphie Und Technologie Mbh Papillomavirusähnliche partikel, fusionsproteine sowie verfahren zu deren herstellung
JP2000515741A (ja) * 1996-07-17 2000-11-28 アメリカ合衆国 感染性パピローマウイルス偽ウイルス粒子
DE19631357A1 (de) * 1996-08-02 1998-02-05 Deutsches Krebsforsch Vektor zur Aktivierung des Immunsystems gegen mit Papillomviren bzw. Sequenzen davon assoziierten Zellen
GB9621091D0 (en) 1996-10-09 1996-11-27 Fondation Pour Le Perfectionem Attenuated microorganisms strains and their uses
CA2275259C (en) * 1996-12-20 2008-02-12 Merck & Co., Inc. Formulations of recombinant papillomavirus vaccines
WO1999001557A1 (en) * 1997-07-03 1999-01-14 University Of Colorado, University Technology Corporation Homogeneous human papilloma virus capsomere containing compositions, methods for manufacture, and the use thereof as diagnostic, prophylactic or therapy
US7351533B2 (en) * 1997-09-05 2008-04-01 Medimmune, Inc. In vitro method for disassmbly/reassembly of papillomavirus virus-like particles (VLPs). Homogeneous VLP and cavsomere compositions produced by said methods: use thereof as vehicle for improved purification, and delivery of active agents
AU2003200653B2 (en) * 1997-10-06 2007-01-18 Loyola University Of Chicago Papilloma virus capsomere vaccine formulations and methods of use
US6228368B1 (en) * 1997-10-06 2001-05-08 Loyola University Of Chicago Papilloma virus capsomere formulations and method of use
CA2229955C (en) 1998-02-20 2003-12-09 Medigene Gmbh Papilloma virus capsomere vaccine formulations and methods of use
US20020039584A1 (en) 1998-02-20 2002-04-04 Medigene Ag Papilloma virus capsomere vaccine formulations and methods of use
US7182947B2 (en) * 1998-02-20 2007-02-27 Medigene Ag Papillomavirus truncated L1 protein and fusion protein constructs
US7494658B2 (en) * 1998-02-20 2009-02-24 Medigene Ag Papilloma virus truncated L1 protein and fusion protein constructs
DE19812940A1 (de) * 1998-03-24 1999-10-07 Medigene Ag Formulierung mit Papillomavirus-spezifischem Protein, seine Herstellung und Verwendung
US6926897B1 (en) * 1998-03-24 2005-08-09 Medigene Aktiengesellschaft Medicament for the avoidance or treatment of papillomavirus-specific tumour
GB9806666D0 (en) * 1998-03-27 1998-05-27 Stanley Margaret Antigen preparation and use
JP4563582B2 (ja) * 1998-08-14 2010-10-13 メルク・シャープ・エンド・ドーム・コーポレイション ヒトパピローマウイルスのウイルス様粒子を使用するタンパク質送達系
US6991795B1 (en) * 1998-08-14 2006-01-31 Merck & Co., Inc. Protein delivery system using human papillomavirus virus-like particles
CA2347099C (en) 1998-10-16 2014-08-05 Smithkline Beecham Biologicals S.A. Adjuvant systems comprising an immunostimulant adsorbed to a metallic salt particle and vaccines thereof
SE514982C2 (sv) * 1999-09-30 2001-05-28 Active Biotech Ab Bärare innehållande ett huvudkapsidprotein L1 från humant papillomavirus samt dess användning
DE19925199A1 (de) 1999-06-01 2000-12-07 Medigene Ag Zytotoxische T-Zellepitope des Papillomavirus L1-Proteins und ihre Verwendung in Diagnostik und Therapie
DE19925235A1 (de) 1999-06-01 2000-12-07 Medigene Ag Zytotoxische T-Zellepitope des Papillomavirus L1-Proteins und ihre Verwendung in Diagnostik und Therapie
US20040146531A1 (en) * 1999-09-30 2004-07-29 Active Biotech Ab Virus-like particles devoid of HPV 16 type-specific antibody epitopes as carriers of peptides for introduction into cells
US6908613B2 (en) * 2000-06-21 2005-06-21 Medimmune, Inc. Chimeric human papillomavirus (HPV) L1 molecules and uses therefor
EP1305039B1 (en) * 2000-07-06 2008-12-31 Georgetown University Stable (fixed) forms of viral l1 capsid proteins, fusion proteins and uses thereof
GB0109297D0 (en) 2001-04-12 2001-05-30 Glaxosmithkline Biolog Sa Vaccine
DE10137102A1 (de) * 2001-07-30 2003-02-27 Deutsches Krebsforsch Polyvalente Vakzine gegen durch Papillomaviren verursachte Erkrankungen, Verfahren zu deren Herstellung und deren Verwendung
GB0206360D0 (en) * 2002-03-18 2002-05-01 Glaxosmithkline Biolog Sa Viral antigens
ES2323634T5 (es) * 2002-05-17 2012-09-04 University Of Cape Town Proteínas quiméricas l1 del virus del papiloma humano 16 que contienen un péptido l2, partículas tipo virus preparadas a partir de estas proteínas y un método para preparar las partículas
US20060088909A1 (en) * 2002-05-17 2006-04-27 Compans Richard W Virus-like particles, methods of preparation, and immunogenic compositions
US9045727B2 (en) * 2002-05-17 2015-06-02 Emory University Virus-like particles, methods of preparation, and immunogenic compositions
US7858098B2 (en) * 2002-12-20 2010-12-28 Glaxosmithkline Biologicals, S.A. Vaccine
US20080160040A1 (en) * 2004-04-15 2008-07-03 Ghim Shin-Je Plant-produced compositions for treating papillomavirus infection and related methods
US7972776B2 (en) * 2005-11-15 2011-07-05 Oncohealth Corporation Protein chips for HPV detection
US7732166B2 (en) * 2005-11-15 2010-06-08 Oncohealth Corporation Detection method for human pappilomavirus (HPV) and its application in cervical cancer
TWI457133B (zh) 2005-12-13 2014-10-21 Glaxosmithkline Biolog Sa 新穎組合物
WO2008082719A2 (en) * 2006-08-30 2008-07-10 University Of Rochester Combined human papillomavirus vlp/gene delivery system and use thereof as a vaccine for prophylaxis and immunotherapy of infectious diseases and tumors
CN101148661B (zh) * 2006-09-18 2013-01-02 中国医学科学院基础医学研究所 人乳头瘤病毒16型外壳蛋白病毒样颗粒及其制备方法和用途
SI2068918T1 (sl) 2006-09-26 2012-09-28 Infectious Disease Res Inst Si - ep sestavek za cepljenje, ki vsebuje sintetiäśna pomagala
US20090181078A1 (en) 2006-09-26 2009-07-16 Infectious Disease Research Institute Vaccine composition containing synthetic adjuvant
US8968995B2 (en) * 2008-11-12 2015-03-03 Oncohealth Corp. Detection, screening, and diagnosis of HPV-associated cancers
US8916342B2 (en) 2006-11-13 2014-12-23 Oncohealth Corp. Identification of high grade or ≧ CIN2 for early stages and late stages detection, screening, and diagnosis of human papillomavirus (HPV) and HPV-associated cancers
US8278056B2 (en) 2008-06-13 2012-10-02 Oncohealth Corp. Detection of early stages and late stages HPV infection
WO2008115631A2 (en) * 2007-02-08 2008-09-25 University Of Louisville Research Foundation, Inc. Plant-produced compositions for treating papillomavirus infection and related methods
PL2137210T3 (pl) 2007-03-02 2017-06-30 Glaxosmithkline Biologicals Sa Nowy sposób i kompozycje
US9364529B2 (en) 2007-04-29 2016-06-14 Beijing Wantai Biological Pharmacy Enterprise Co., Ltd. Truncated L1 protein of human papillomavirus type 18
US9428555B2 (en) 2007-04-29 2016-08-30 Beijing Wantai Biological Pharmacy Enterprise Co., Ltd. Truncated L1 protein of Human Papillomavirus type 16
EP2154149B1 (en) * 2007-05-29 2019-07-10 Xiamen University A truncated l1 protein of human papillomavirus 6
CA2703066A1 (en) * 2007-10-22 2009-04-30 University Of Rochester Respiratory syncytial virus vaccine based on chimeric papillomavirus virus-like particles or capsomeres
EP2223933B1 (en) * 2007-11-23 2016-01-27 Shanghai Zerun Biotechnology Co., Ltd. Genes encoding major capsid protein l1 of human papilloma viruses
GB0815872D0 (en) 2008-09-01 2008-10-08 Pasteur Institut Novel method and compositions
GB0820822D0 (en) 2008-11-13 2008-12-24 Inst Catala D Oncologia Novel product and processes
RU2732574C2 (ru) 2009-06-05 2020-09-21 Инфекшес Дизиз Рисерч Инститьют Синтетические глюкопиранозиллипидные адъюванты
EP2521914A4 (en) 2010-01-08 2013-07-10 Oncohealth Corp CELL-BASED HPV IMMUNOTESTS HAVE A HIGH PERFORMANCE FOR DIAGNOSIS AND SCANNING OF HPV ASSOCIATED CANCER
CA2832307A1 (en) 2011-04-08 2012-10-18 Immune Design Corp. Immunogenic compositions and methods of using the compositions for inducing humoral and cellular immune responses
SG195383A1 (en) * 2011-06-14 2013-12-30 Globeimmune Inc Yeast-based compositions and methods for the treatment or prevention of hepatitis delta virus infection
EP2723371B1 (en) 2011-06-24 2019-10-23 Merck Sharp & Dohme Corp. Hpv vaccine formulations comprising aluminum adjuvant and methods of producing same
EP2990477B8 (en) 2011-09-08 2018-10-31 uniQure IP B.V. Removal of contaminating viruses from aav preparations
CN110339160A (zh) 2012-02-07 2019-10-18 传染性疾病研究院 包含tlr4激动剂的改进佐剂制剂及其使用方法
US20150110824A1 (en) 2012-03-18 2015-04-23 Glaxosmithkline Biologicals, Sa Method of vaccination against human papillomavirus
NZ701881A (en) 2012-05-16 2016-10-28 Immune Design Corp Vaccines for hsv-2
AU2014253791B2 (en) 2013-04-18 2019-05-02 Immune Design Corp. GLA monotherapy for use in cancer treatment
US9463198B2 (en) 2013-06-04 2016-10-11 Infectious Disease Research Institute Compositions and methods for reducing or preventing metastasis
CN104231060B (zh) * 2013-06-05 2018-05-15 厦门大学 人乳头瘤病毒l1l2衣壳蛋白相互作用位点及其应用
EA201691348A1 (ru) 2013-12-31 2016-11-30 Инфекшес Дизиз Рисерч Инститьют Однофлаконные вакцинные составы
MX2018013640A (es) 2016-05-16 2019-08-01 Infectious Disease Res Inst Liposomas pegiladas y metodos de uso.
ES2929054T3 (es) 2016-05-16 2022-11-24 Access To Advanced Health Inst Formulación que contiene un agonista de TLR y métodos de uso
KR20220165789A (ko) 2016-06-01 2022-12-15 액세스 투 어드밴스드 헬스 인스티튜트 사이징제를 함유하는 나노명반 입자
MX2019015076A (es) 2017-06-15 2020-08-03 Infectious Disease Res Inst Portadores lípidos nanoestructurados y emulsiones estables y usos de los mismos.
AU2018330165A1 (en) 2017-09-08 2020-04-02 Access To Advanced Health Institute Liposomal formulations comprising saponin and methods of use
JP7491932B2 (ja) * 2018-12-28 2024-05-28 ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー 操作されたｂ型肝炎コアポリペプチド
EP3976092A1 (en) 2019-05-25 2022-04-06 Infectious Disease Research Institute Composition and method for spray drying an adjuvant vaccine emulsion
CN114127295B (zh) * 2019-07-19 2024-05-14 神州细胞工程有限公司 嵌合的人乳头瘤病毒16型l1蛋白
CN114127099B (zh) * 2019-07-19 2024-04-19 神州细胞工程有限公司 嵌合的人乳头瘤病毒6型l1蛋白
CN114127097B (zh) * 2019-07-19 2024-09-17 神州细胞工程有限公司 嵌合的人乳头瘤病毒56型l1蛋白
WO2021013073A1 (zh) 2019-07-19 2021-01-28 神州细胞工程有限公司 嵌合的乳头瘤病毒l1蛋白
CA3147849A1 (en) 2019-07-19 2021-01-28 Sinocelltech Ltd. Polyvalent immunogenicity composition for human papillomavirus
WO2021163002A1 (en) 2020-02-14 2021-08-19 Merck Sharp & Dohme Corp. Hpv vaccine
US20230310323A1 (en) 2020-09-04 2023-10-05 Access To Advanced Health Institute Co-lyophilized rna and nanostructured lipid carrier
CN114539363B (zh) * 2020-11-26 2023-12-01 中国医学科学院基础医学研究所 一种c端改造的人乳头瘤病毒11型l1蛋白及其用途
CN114539365B (zh) * 2020-11-26 2023-12-01 中国医学科学院基础医学研究所 一种改造的人乳头瘤病毒52型l1蛋白及其用途
JP2024506364A (ja) 2021-02-11 2024-02-13 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム Ｈｐｖワクチンの製造
US20240287545A1 (en) 2021-06-21 2024-08-29 Uniqure Biopharma B.V. Improved lysis procedures
US20230048144A1 (en) 2021-08-06 2023-02-16 Merck Sharp & Dohme Llc Hpv vaccine
WO2023023152A1 (en) 2021-08-19 2023-02-23 Merck Sharp & Dohme Llc Thermostable lipid nanoparticle and methods of use thereof
WO2024052882A1 (en) 2022-09-09 2024-03-14 Access To Advanced Health Institute Immunogenic vaccine composition incorporating a saponin

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993002184A1 (en) * 1991-07-19 1993-02-04 The University Of Queensland Papilloma virus vaccine
WO1994020137A1 (en) * 1993-03-09 1994-09-15 University Of Rochester Production of human papillomavirus capsid protein and virus-like particles
JPH10506796A (ja) * 1994-10-06 1998-07-07 ザ ガヴァメント オブ ザ ユナイテッド ステイツ オブ アメリカ、アズ レプリゼンテッド バイ ザ セクレタリー、デパートメント オブ ヘルス アンド ヒューマン サーヴィスィズ パピローマウイルス様キメラ粒子

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9113809D0 (en) * 1991-06-26 1991-08-14 Cancer Res Campaign Tech Papillomavirus l2 protein
GB9207701D0 (en) 1992-04-08 1992-05-27 Cancer Res Campaign Tech Papillomavirus e7 protein
WO1993020840A1 (en) * 1992-04-14 1993-10-28 British Bio-Technology Limited Induction of ctl responses
DE122007000099I1 (de) 1992-06-25 2008-03-27 Papillomavirus vakzine
US5437951A (en) * 1992-09-03 1995-08-01 The United States Of America As Represented By The Department Of Health And Human Services Self-assembling recombinant papillomavirus capsid proteins
US6153201A (en) * 1993-03-09 2000-11-28 University Of Rochester Oral immunization with papillomavirus virus-like particles
WO1996011272A2 (de) * 1994-10-07 1996-04-18 Medigene Gesellschaft Für Molekularbiologische Diagnostik, Theraphie Und Technologie Mbh Papillomavirusähnliche partikel, fusionsproteine sowie verfahren zu deren herstellung
JP3958360B2 (ja) * 1995-02-24 2007-08-15 キャンタブ ファーマシューティカルズ リサーチ リミティド 免疫治療剤として役立つポリペプチド及びポリペプチド調製の方法
US5874089A (en) * 1995-10-02 1999-02-23 Georgetown University School Of Medicine Protecting against canine oral papillomavirus (copy)
US6228368B1 (en) * 1997-10-06 2001-05-08 Loyola University Of Chicago Papilloma virus capsomere formulations and method of use

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993002184A1 (en) * 1991-07-19 1993-02-04 The University Of Queensland Papilloma virus vaccine
WO1994020137A1 (en) * 1993-03-09 1994-09-15 University Of Rochester Production of human papillomavirus capsid protein and virus-like particles
JPH10506796A (ja) * 1994-10-06 1998-07-07 ザ ガヴァメント オブ ザ ユナイテッド ステイツ オブ アメリカ、アズ レプリゼンテッド バイ ザ セクレタリー、デパートメント オブ ヘルス アンド ヒューマン サーヴィスィズ パピローマウイルス様キメラ粒子

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
JPN4006005801; Ｊ．Ｖｉｒｏｌ．，Ｖｏｌ．６８，Ｎｏ．２（１９９４．Ｆｅｂ．）ｐ．６１９-６２５ *
JPN4006005802; Ｖｉｒｏｌｏｇｙ，Ｖｏｌ．１８５，Ｎｏ．２（１９９１）ｐ．６２５-６３２ *

Also Published As

Publication number Publication date
ES2264563T3 (es) 2007-01-01
US7416732B2 (en) 2008-08-26
EP0809700B1 (de) 2006-05-10
US6361778B1 (en) 2002-03-26
JP2015037430A (ja) 2015-02-26
EP0809700A1 (de) 1997-12-03
PT809700E (pt) 2006-09-29
US6066324A (en) 2000-05-23
JP2012010713A (ja) 2012-01-19
CA2202090C (en) 2012-04-17
US20040202679A1 (en) 2004-10-14
LU91390I2 (fr) 2008-02-14
NL300323I1 (nl) 2008-03-03
JPH11504801A (ja) 1999-05-11
JP2013213034A (ja) 2013-10-17
AU1010600A (en) 2000-03-16
US6599508B1 (en) 2003-07-29
ATE325875T1 (de) 2006-06-15
DE122007000093I1 (de) 2008-03-27
NL300324I1 (nl) 2008-03-03
LU91401I2 (fr) 2008-02-14
AU760615B2 (en) 2003-05-22
JP5794747B2 (ja) 2015-10-14
US20110015376A1 (en) 2011-01-20
NL300323I2 (nl) 2010-03-01
CA2202090A1 (en) 1996-04-18
JP2005270111A (ja) 2005-10-06
DE59511047D1 (de) 2006-06-14
DK0809700T3 (da) 2006-09-18
WO1996011272A3 (de) 1996-09-26
AU4270196A (en) 1996-05-02
WO1996011272A2 (de) 1996-04-18
DE122007000092I1 (de) 2008-03-27
EP1728800A1 (de) 2006-12-06
US20060153864A1 (en) 2006-07-13

Similar Documents

Publication Publication Date Title
JP2009102327A (ja) パピローマウイルス様粒子、融合タンパク質並びにそれらの製造方法
DE122011100018I1 (de) Herstellung von menschlichem Papilloma-Virus-Capsid-Protein und virusahnlichen Teilchen.
DE69535018D1 (de) Papillomavirus vakzine
ATE288489T1 (de) Vp-antigene des jc-virus
HUP0004327A3 (en) Fusion proteins containing human papilloma virus (hpv) proteins and immunological fusion partner with t-helper epitopes to the hpv antigen, as well as vaccine formulations for treatment and/or profilaxis of hpv induced lesions
EP1105157A4 (en) PROTEIN ADMINISTRATION SYSTEM USING PARTICLES LIKE THE HUMAN PAPILLOMAVIRUS.
DK0750669T3 (da) Modificeret papillomavirus-L2-protein og VLP'er dannet derudfra
CA2295316A1 (en) Homogeneous human papilloma virus capsomere containing compositions, methods for manufacture, and the use thereof as diagnostic, prophylactic or therapy

Legal Events

Date Code Title Description
A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20110406

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20110705

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20110708

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20110805

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20110810

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20110905

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20110908

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20111004

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20111021

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20111222

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20111228

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20130129

A761 Written withdrawal of application

Free format text: JAPANESE INTERMEDIATE CODE: A761

Effective date: 20130527